Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 June 2023 | Story Dr Nokuthula Tlalajoe-Mokhatla | Photo Supplied
Dr Nokuthula Tlalajoe-Mokhatla
Dr Nokuthula Tlalajoe-Mokhatla, Academic Head and Senior Lecturer at the Division of Student Learning and Development.

The University of the Free State (UFS) is celebrating Youth Month by showcasing the positive influence of the institution on career development. As part of this initiative, we are sharing the stories of UFS alumni who are now working at the university.

Dr Nokuthula Tlalajoe-Mokhatla, Academic Head and Senior Lecturer at the Division of Student Learning and Development, shares her UFS journey:

Q: Year of graduation from the UFS:

A: I graduated in 2010, 2011, 2013, and 2021 (virtual graduation).

Q: Qualification obtained from the UFS:
A: BSc Biochemistry and Microbiology, BSc Honours Biochemistry, MSc Biochemistry (Cum Laude), PhD in Health Professions Education

Q: Date of joining the UFS as a staff member:
A: I joined as an official staff member on 18 January 2016; however, I have been in the HR system since my third year (2009) when I was appointed as a Laboratory Assistant.

Q: Initial job title and current job title:

A: In the context of point 3, I would safely say I moved from Laboratory Assistant, to Demonstrator, to Lecturer, and now Academic Head of the division and Senior Lecturer.

Q: How did the UFS prepare you for the professional world?

A: Every human being can be taught a skill, be it a scientist, health professional, or accountant. However, how their soft skills complement or lack to complement the core knowledge and application will set that individual apart. That being said, I have utilised the vast opportunities that are always accessible to enhance one's development with regard to lifelong learning skills. My biggest gain was the Engaged Leadership Programme (middle management level), which I completed in 32 weeks and obtained a distinction. That type of training set me in a position that could easily have played a role in me being able to progress further in the professional world.

Q: What are your thoughts on transitioning from a UFS alumnus to a staff member?

A: The outlook is so different when you are a staff member. I am enjoying the world of being a staff member more. This is due to my struggles as a student – a story for another day. The perks and benefits are more as a staff member, and your world gets bigger and bigger. Networking with like-minded people and contributing to day-to-day activities is mind-blowing for me.

Q: Any additional comments about your experience?
A: I appreciate the support systems in our setting; it comes in handy when we doubt ourselves and think we are not enough or adequate. What I do appreciate is the opportunities that are accessible, and with the help we have in place, it brings a sense of ease to know you can equally access it.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept